link to customer portal 

Pharmaview
Invaluable Corporate and Commercial Analysis of the Biopharmaceutical Industry

Acquired from Wood Mackenzie in December 2007, the Pharmaview team is a recent addition to the Decision Resources group, and provides an established expertise in corporate research on the biopharmaceutical industry stretching back more than 20 years. 

Pharmaview provides continually updated analysis on over 1500 marketed and pipeline products from over 120 companies, covering 136 product classes and 14 therapy areas- complete with seven-year product-level forecasts for over 1000 products. 

In addition, Pharmaview provides in-depth analysis on the Top 50 pharmaceutical and biotechnology companies as measured by ethical drug sales, including geographic, therapeutic and business development strategies, coverage of major strategic moves and product / technology deals, as well as the key issues facing each company.

Pharmaview offers all the insight you need to understand how each player in the biopharmaceutical industry functions. Therapeutic analysis, individual company breakdown, and the impact of major events in the industry are all contained in a subscription to Pharmaview.

Therapy Analysis
Our Therapy Analysis provides access to disease area overviews, therapy area rankings by company and licensing deal overviews. In addition, product portfolios and sales forecasts can be viewed by individual therapeutic class and by individual companies participating in a specific therapy area.

Therapy Analysis includes:

• Continually updated research and analysis on over 1500 marketed and pipeline products from over 120 companies, across 136 product classes and 14 therapy areas
• Transparent sales forecasts, backed up with qualitative assumptions, for over 1000 marketed and pipeline products, providing insight into which therapies are predicted to drive growth
• Sales rankings of the leading companies in each therapy area, with the ability to view performance by sales, market share or sales growth
• Analysis of the current state of key therapeutic areas, together with likely strategic development plans for each participating company
• Major events by therapeutic area

Company Analysis
Updated on a monthly basis with the latest news and analysis, our company research provides independent and objective insight into the strategy, business development activities, financials, historical and forecasted sales, for the Top 50 pharmaceutical and biotechnology companies, ranked by ethical drug sales.

Company Analysis includes:

• Key issues facing each company
• Corporate, geographic, therapeutic and business development strategies
• Coverage of major strategic moves and product / technology deals
• Continually updated analysis of marketed products and R&D candidates, including historic sales data and independent seven-year forecasts by company
• Detailed analysis on the leading franchises for each company, including key strategic initiatives, the life-cycle management of key products, and a comprehensive SWOT analysis of each franchise
• Major company events

Industry Analysis
Providing up-to-date insight into the industry-wide and territory-specific issues shaping the pharmaceutical industry, our Industry Analysis helps busy executives cut through the news flow and understand the impact of key events. Clients also have access to our invaluable Executive's Guide.

Industry Analysis includes:

• Concise and comparable analysis, together with key reference data and ready-to-use graphics, focusing on the healthcare / pharmaceutical environment in the G7, and the emerging markets
• Monthly event reports covering key industry developments and their potential impact on the global pharmaceutical and biotechnology markets
• Background reports providing summaries of the structure and key features of each country's healthcare and pharmaceutical market
• Industry rankings of companies, products and therapy areas

Productview Plus
Quantified, Event-Driven Forecasts

Productview Plus offers a unique, trustworthy user-defined approach to forecasting. The Productview Plus model is updated 3 times a year and allows you to import your own data, add new drugs, and modify / import quantified events, providing:

Clarity:
All of the assumptions behind the events used to create the forecasts are clear and quantified

Ease of use:
The intuitive nature of the models gives you the ability to change the impact of the included events to create your own, user-defined forecasts

Consistency:
The model employs a standardized methodology so that multiple TAs can be forecast in the same manner

Productview Plus is a downloadable, interactive Excel-based tool allowing one-click navigation to:

• Event-driven forecasts which can be altered to reflect your view on future sales potential
• Independent data covering:
  - Over 1000 marketed and pipeline products
  - 136 product classes across 14 therapy areas
  - Five years' historical data and a seven-year forecast window
• Multiple therapeutic area models with forecasts split US/ROW:

Executive’s Guide
To the world’s leading pharmaceutical and biotechnology companies

The Executive's Guide 2008 is an indispensable reference for those seeking a strategic insight into the biopharmaceutical industry and its major players. This year's edition - the 21st to date - provides a snapshot of the world's top 25 pharmaceutical and biotechnology companies, ranked by ethical drug sales, and includes an analysis of the key issues facing each company, their strategies, portfolios and pipelines. Each company executive summary also includes a breakdown of ethical drug sales by geography and therapeutic area, company earnings-per-share and dividend-per-share performance, as well as a five-year portfolio freshness index.

In addition, the Executive's Guide 2008 ranks the top 100 ethical drugs by sales, and identifies the key themes that will affect the industry in the near-term. It also explores the major products and players in 14 different therapy areas, and looks at the underlying factors affecting the dynamics of these therapy areas.

The 2008 edition includes:

• Analysis of the four key issues facing the industry in the near-term
• The top 100 ethical drugs ranked by sales in 2007
• Analysis of the 14 major therapy areas, including key products, sales and growth rates
• The top 25 pharmaceutical and biotechnology companies ranked by 2007 ethical drug sales
• Executive summaries for each of the top 25 pharmaceutical and biotechnology companies
• Analysis of the dividend growth and share repurchases for the top 10 companies in 2007